Valuation : Abivax

Market Cap 8.8B 10.24B 8.28B 7.56B 14.1B 971B 14.18B 98.1B 37.94B 496B 38.43B 37.58B 1,572B P/E 2026 *
-28.5x
P/E 2027 * -33.5x
Enterprise Value 7.7B 8.95B 7.24B 6.61B 12.34B 849B 12.4B 85.81B 33.19B 434B 33.62B 32.87B 1,375B EV / Sales 2026 *
103x
EV / Sales 2027 * 94.4x
Free-Float
92.81%
Yield 2026 *
-
Yield 2027 * -
1 day+3.11%
1 week+3.54%
Current month+3.54%
1 month-11.48%
3 months+14.97%
6 months+7.45%
Current year-16.11%
1 week 96.4
Extreme 96.4
101.7
1 month 95
Extreme 95
114.8
Current year 60.45
Extreme 60.45
139
1 year 60.45
Extreme 60.45
139
3 years 4.51
Extreme 4.51
139
5 years 4.51
Extreme 4.51
139
10 years 3.9
Extreme 3.9
139
Manager TitleAgeSince
Chief Executive Officer 68 2023-05-04
Director of Finance/CFO 63 2017-01-01
Chief Tech/Sci/R&D Officer - 2023-09-30
Director TitleAgeSince
Chairman 66 2022-08-15
Chairman 68 2023-05-04
Director/Board Member 60 2023-07-10
Date Insider Type Main position Quantity % Market Cap. Importance
7/15/26 Sell

Chairman

-3,375 0.0042%
7/11/26 Exercice

Chief Executive Officer

17,728 0.0222%
7/11/26 Exercice

Chairman

12,500 0.0157%
Change 5-day change 1-year change 3-year change Capi.($)
+3.11%+3.54%+32.03%+481.80% 9.93B
-0.82%-3.57%-3.71%+12.92% 48.41B
-1.29%+0.85%+411.90%+546.06% 45.01B
-3.20%-0.76%+38.11%+18.36% 44.07B
-1.89%-2.25%+2.83%+80.93% 40.73B
-1.72%-3.07%+13.76%+43.40% 33.21B
-0.17%+2.68% - - 17.77B
-0.07%-0.52%+21.34%+117.49% 16.5B
-0.56%-1.85%+11.53%+30.40% 14.45B
-2.68%-2.60%+71.21%+37.36% 13.77B
Average -0.93%+0.22%+66.56%+152.08% 28.39B
Weighted average by Cap. -1.38%-0.11%+84.30%+144.42%

Financials

2026 *2027 *
Net sales 74.92M 87.11M 70.48M 64.32M 120M 8.26B 121M 835M 323M 4.22B 327M 320M 13.38B 82.73M 96.19M 77.82M 71.03M 133M 9.12B 133M 922M 357M 4.66B 361M 353M 14.77B
Net income -265M -308M -249M -228M -425M -29.23B -427M -2.95B -1.14B -14.94B -1.16B -1.13B -47.33B -231M -268M -217M -198M -370M -25.44B -372M -2.57B -994M -13B -1.01B -985M -41.19B
Net Debt -1.1B -1.28B -1.04B -947M -1.77B -122B -1.78B -12.29B -4.75B -62.13B -4.81B -4.71B -197B -993M -1.15B -934M -852M -1.59B -109B -1.6B -11.06B -4.28B -55.94B -4.33B -4.24B -177B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
80
Date Price Change Volume
26-09-08 €101.00 +3.11% 120,091
26-09-07 €97.95 +0.36% 88,803
26-09-04 €97.60 -1.56% 61,886
26-09-03 €99.15 +2.59% 118,999
26-09-02 €96.65 -1.83% 106,964
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
101.00EUR
Average target price
138.97EUR
Spread / Average Target
+37.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABVX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!